SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: A systematic review and network meta-analysis

BMJ Open

Volumn 6, Issue 2, 2016, Pages

  Shyangdan, Deepson S ^a   Uthman, Olalekan A ^a   Waugh, Norman ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; HEMOGLOBIN A1C; LUSEOGLIFLOZIN; PLACEBO; TOFOGLIFLOZIN; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; 6-((4-ETHYLPHENYL)METHYL)-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO(ISOBENZOFURAN-1(3H),2'-(2H)PYRAN)-3',4',5'-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2; SORBITOL;

ARTICLE; HEMOGLOBIN BLOOD LEVEL; HUMAN; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BAYES THEOREM; BLOOD; BLOOD PRESSURE; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM;

BAYES THEOREM; BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL; WEIGHT LOSS;

EID: 84960433486     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009417     Document Type: Article

References (30)

1. National Institute for Health and Care Excellence. NICE Guidance TA288. Dapagliflozin in combination therapy for treating type 2 diabetes. Secondary NICE Guidance TA288. Dapagliflozin in combination therapy for treating type 2 diabetes. 2013. http://www.nice.org.uk/guidance/TA288/chapter/1-guidance
2. National Institute for Health and Care Excellence. NICE Guidance TA315. Canagliflozin in combination therapy for treating type 2 diabetes. Secondary NICE Guidance TA315. Canagliflozin in combination therapy for treating type 2 diabetes 2014. http://www.nice.org.uk/guidance/TA315/chapter/1-guidance
3. National Institute for Health and Care Excellence. Empagliflozin combination therapy for treating type 2 diabetes [ID641] GID-TAG441. Secondary Empagliflozin combination therapy for treating type 2 diabetes [ID641] GID-TAG441 2014. http://www.nice.org.uk/guidance/indevelopment/GID-TAG441
4. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion results of a randomized, placebo-controlled study. Diabetes Care 2013;36:2154-61.
5. Stein P, Berg JK, Morrow L, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metab Clin Exp 2014;63:1296-303.
6. Higgins J, Green S, Collaboration TC. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Secondary Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. 2011. http://www.cochrane.org/handbook
7. Veroniki AA, Vasiliadis HS, Higgins JP, et al. Evaluation of inconsistency in networks of interventions. Int J Epidemiol 2013;42:332-45.
8. Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med 2013;11:159.
9. Higgins JPT, Jackson D, Barrett JK, et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012;3:98-110.
10. Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932-44.
11. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-31.
12. Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012;66:446-56.
13. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82.
14. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33.
15. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24.
16. Haring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014;37:1650-9.
17. Ji L, Ma J, Li H, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther 2014;36:84-100.e9.
18. Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:432-40.
19. Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013;56:2582-92.
20. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013;1:208-19.
21. Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014;30:1245-55.
22. Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study. Expert Opin Pharmacother 2014;15:1501-15.
23. Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014;13:65.
24. Kashiwagi A, Kazuta K, Goto K, et al. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2015;17:304-8.
25. Cooper NJ, Peters J, Lai MC, et al. How valuable are multiple treatment comparison methods in evidence-based health-care evaluation? Value Health 2011;14:371-80.
26. Thorlund K, Mills EJ. Sample size and power considerations in network meta-analysis. Syst Rev 2012;1:41.
27. National Institute for Health and Care Excellence. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes [ID756] GID-TAG471. Secondary canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes [ID756] GID-TAG471 2015. http://www.nice.org.uk/guidance/indevelopment/GID-TAG471
28. Pacou M, Taieb V, Abrams KR, et al. Bayesian network meta-analysis to assess relative efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin. Value Health 2013;16:A609.
29. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predipose to ketoacidosis. J Clin Endocrinol Metab 2015;100:2849-52.
30. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransported 2 inhibition. Diabetes Care 2015;38:1687-93.